KineMed, Inc. Receives U.S. Patent Allowance For Noscapine To Treat ALS, Parkinson’s Disease, And Diabetic Neuropathy
9/4/2014 11:00:14 AM
EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. (www.kinemed.com) today announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: “Compositions and Methods of Treatment Using Modulators of Motoneuron Disease.” The patent allowance covers the treatment of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, Parkinson’s disease, and diabetic neuropathy using the microtubule target modulating agent, noscapine, alone or in combination with a variety of other agents.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by